Filed by Azur Pharma Limited
Pursuant to Rule 425 under The Securities Act of 1933
And Deemed Filed Pursuant to Rule 14a-12
Under the Securities Exchange Act of 1934
Subject Company: Jazz Pharmaceuticals, Inc.
Commission File Number: 001-33500
Date: October 19, 2011

The following is a slide presentation relating to the proposed transactions described therein that was made available beginning on October 18, 2011.

Introduction to Jazz Pharmaceuticals

Bruce Cozadd
Chairman and CEO

October 18, 2011

Jazz Pharmaceuticals
Innovation that performs

Forward-Looking Statements

"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995

This presentation contains forward-looking statements, including, but not limited to, statements related to the anticipated consummation of the business combination transaction between Jazz Pharmaceuticals and Azur Pharma and the timing and benefits thereof, the combined company's, and each respective company's, strategy, plans, objectives, expectations (financial or otherwise) and intentions, future financial results and growth potential (including Jazz Pharmaceuticals' 2011 Financial Guidance), anticipated product portfolio, development programs, intellectual property and tax position, management structure, and other statements that are not historical facts. These forward-looking statements are based on Jazz Pharmaceuticals' current expectations and inherently involve significant risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward looking statements as a result of these risks and uncertainties, which include, without limitation, risks related to Jazz Pharmaceuticals' ability to complete the transaction on the proposed terms and schedule; risks associated with business combination transactions, such as the risk that the businesses will not be integrated successfully or that such integration may be more difficult, time-consuming or costly than expected; risks related to future opportunities and plans for the combined company, including uncertainty of the expected financial performance and results of the combined company following completion of the proposed transaction; disruption from the proposed transaction, making it more difficult to conduct business as usual or maintain relationships with customers, employees or suppliers; the calculations of, and factors that may impact the calculations of, the acquisition price in connection with the proposed merger and the allocation of such acquisition price to the net assets acquired in accordance with applicable accounting rules and methodologies; and the possibility that if the combined company does not achieve the perceived benefits of the proposed transaction as rapidly or to the extent anticipated by financial analysts or investors, the market price of the combined company's shares could decline, as well as other risks related to Jazz Pharmaceuticals' business, including Jazz Pharmaceuticals' dependence on sales of Xyrem® and its ability to increase sales of its Xyrem and Luvox CR® products; competition, including potential generic competition; Jazz Pharmaceuticals' dependence on single source suppliers and manufacturers; the ability of Jazz Pharmaceuticals to protect its intellectual property and defend its patents; regulatory obligations and oversight; Jazz Pharmaceuticals cash flow; and those risks detailed from time-to-time under the caption "Risk Factors" and elsewhere in Jazz Pharmaceuticals' SEC filings and reports, including in its Quarterly Report on Form 10-Q for the quarter ended June 30, 2011. Jazz Pharmaceuticals undertakes no duty or obligation to update any forward-looking statements contained in this presentation as a result of new information, future events or changes in its expectations.

Additional Information

Additional Information and Where to Find It

In connection with the proposed business combination transaction described in this presentation, Jazz Pharmaceuticals and Azur Pharma will be filing documents with the SEC, including the filing by Jazz Pharmaceuticals of a preliminary and definitive proxy statement/prospectus relating to the proposed transaction and the filing by Azur Pharma of a registration statement on Form S-4 that will include the proxy statement/prospectus relating to the proposed transaction. After the registration statement has been declared effective by the SEC, a definitive proxy statement/prospectus will be mailed to Jazz Pharmaceuticals stockholders in connection with the proposed transaction. INVESTORS AND SECURITY HOLDERS ARE URGED TO READ THE REGISTRATION STATEMENT ON FORM S-4 AND THE RELATED PRELIMINARY AND DEFINITIVE PROXY/PROSPECTUS WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT JAZZ PHARMACEUTICALS, AZUR PHARMA AND THE PROPOSED TRANSACTION. Investors and security holders may obtain free copies of these documents (when they are available) and other related documents filed with the SEC at the SEC's web site at www.sec.gov, by directing a request to Jazz Pharmaceuticals' Investor Relations department at Jazz Pharmaceuticals, Inc., Attention: Investor Relations, 3180 Porter Drive, Palo Alto, California 94304, or to Jazz Pharmaceuticals' Investor Relations department at 650-496-2800 or by email to investorinfo@jazzpharma.com. Investors and security holders may obtain free copies of the documents filed with the SEC on Jazz Pharmaceuticals' website at www.jazzpharmaceuticals.com under the heading "Investors" and then under the heading "SEC Filings." Jazz Pharmaceuticals and its directors and executive officers and Azur Pharma and its directors and executive officers may be deemed participants in the solicitation of proxies from the stockholders of Jazz Pharmaceuticals in connection with the proposed transaction. Information regarding the special interests of these directors and executive officers in the proposed transaction will be included in the proxy statement/prospectus described above. Additional information regarding the directors and executive officers of Jazz Pharmaceuticals is also included in Jazz Pharmaceuticals' proxy statement for its 2011 Annual Meeting of Stockholders, which was filed with the SEC on April 12, 2011. These documents are available free of charge at the SEC's web site at www.sec.gov and from Investor Relations at Jazz Pharmaceuticals as described above.

This communication does not constitute an offer to sell, or the solicitation of an offer to sell, or the solicitation of an offer to subscribe for or buy, any securities nor shall there be any sale, issuance or transfer of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.

For full prescribing information refer to product websites.

Building Shareholder Value by Focusing on Patient Needs

Jazz Pharmaceuticals' mission is to improve patients' lives by identifying, developing and commercializing valuable pharmaceutical products in focused therapeutic areas

Strategy to Build Shareholder Value

4 **Maintain entrepreneurial, ownership culture at the company**

Make disciplined resource allocation decisions

Current Business and Financial Overview

Xyrem - Strong Sales Growth

2011 Guidance $215M-$225M[1]



1. Based on guidance provided on July 28, 2011. The company is not updating the prior guidance and actual results may differ.

Xyrem is a Standard of Care in Narcolepsy

- Only FDA-approved product for both cataplexy and excessive daytime sleepiness in patients with narcolepsy
  - Marketed in U.S. since 2002
  - Marketed in major European countries by UCB and in Canada by Valeant

- Currently marketed in U.S. by 110-person specialty sales force
- Approximately 8,700 patients on therapy, usually in conjunction with stimulant therapy
- Distributed under proprietary Xyrem Success Program®

The Burden of Narcolepsy

- Affects 1 in 2000 in US[1]
  - ≈ multiple sclerosis and Parkinson's disease[2]
  - > cystic fibrosis[3]
- Although narcolepsy is thought to affect between 125,000 and 200,000 Americans, only about 50,000 are diagnosed[4]
- Key symptoms can be debilitating
  - Cataplexy occurs in 60%-100% of patients
  - 100% experience excessive daytime sleepiness

1. National Institute of Neurological Disorders and Stroke. http://www.ninds.nih.gov/disorders/narcolepsy/detail_narcolepsy.htm. Accessed March 17, 2011.
2. Narcolepsy Sleep Foundation. www.sleepfoundation.org/article/sleep-related-problems/narcolepsy-and-sleep. Accessed March 17, 2011.
3. Zemanick et al. J Cyst Fibros. 2010;9:1-16.
4. American Sleep Association. http://www.sleepassociation.org/index.php?p=aboutnarcolepsy. Accessed March 17, 2011.

Xyrem has Demonstrated Effect on Two Key Symptoms of Narcolepsy

Improvement in Epworth Sleepiness Scale[1]



Reduction in Weekly Cataplexy Attacks[2]



1. Trial 3: From a 8-week, multicenter, randomized, double-blind, placebo controlled, parallel-arm trial of narcolepsy patients (N=228) with moderate to severe EDS and cataplexy symptoms. Antidepressants were withdrawn prior to randomization and stimulants were continued throughout the study at stable doses. In XYREM clinical trials, ≥80% of patients maintained concomitant stimulant use. XYREM International Study Group. *J Clin Sleep Med.* 2005;1:391.
2. Trial 1: From a 4-week, double-blind, placebo-controlled trial of narcolepsy patients (N=136) with moderate to severe cataplexy (median of 21 attacks per week) comparing the effects of three doses of orally administered sodium oxybate with placebo for the treatment of narcolepsy. Patients continued to receive stable stimulant therapy throughout the study. The US XYREM Multicenter Study Group. *Sleep.* 2002;25(1):42-29.

Most Common Adverse Events in Controlled Studies of Xyrem

Adverse Event[1]	% of Patients (N=655)	
	Placebo[2]	Xyrem[3]
Nausea	4	19
Dizziness	4	18
Headache	15	18
Vomiting	1	8
Somnolence	4	6
Urinary incontinence[4]	<1	6
Nasopharyngitis	5	6

Label includes boxed warning that sodium oxybate is a central nervous system depressant with abuse potential and should not be used with alcohol or other CNS depressants. See complete boxed warning at end of presentation.

1. Occurring in 5% of XYREM patients and more frequently than with placebo. 2. Data on file, Jazz Pharmaceuticals, Inc. 3. XYREM (sodium oxybate) PI. 4. Generally nocturnal enuresis.

Strong Sodium Oxybate Patent Coverage

	Number	Issue Date	Expiration Date
Distribution system patent*	7,765,106	7/27/2010	6/16/2024
Distribution system patent*	7,765,107	7/27/2010	6/16/2024
Distribution system patent	7,797,171	9/14/2010	6/16/2024
Distribution system patent*	7,668,730	2/23/2010	6/16/2024
Distribution system patent*	7,895,059	2/23/2011	12/17/2022
Formulation patent*	6,780,889	8/24/1999	7/4/2020
Formulation patent*	7,262,219	8/28/2007	7/4/2020
Process patent	6,472,431	10/29/1999	12/22/2019
Method of use patent*	7,851,506	12/14/2010	12/22/2019

* Listed in FDA Orange Book

Overview of Manufacturing and Distribution

- DEA drug quota needed to manufacture controlled “Schedule I” API
- Exclusive relationships with API supplier and finished goods manufacturer
- Unique proprietary distribution system uses exclusive single pharmacy
- Risk management program and unique product attributes require high touch commercial capabilities

Current Xyrem Patient Coverage Distribution*

- Approximately 90% of insured patients have access
- Relatively low rates of required prior authorizations
- Low monthly out-of-pocket (OOP) expenses
  - Over 70% of patients have monthly OOP of ≤ $50



* Company data and MediMedia Formulary Compass July 2011.

Xyrem Growth Initiatives

Increased Marketing Investment

- New narcolepsy physician targets
- Xyrem Success Program education
- Patient services
  - Nursing program
  - Xyrem Patient Connection
  - Patient assistance programs

Improve Market Penetration Over Time

Current Patients = ~ 8,700
Approximately 17% of 50K Diagnosed Narcolepsy Patients

Luvox CR® - Important Treatment Option for OCD

- Indicated for obsessive compulsive disorder (OCD)
- OCD affects ~ 2.2 million Americans[1,2]
  - Often underdiagnosed[3,4]
  - Difficult to differentiate from comorbidities[5]
- Only 43% of adults newly diagnosed with OCD received adequate treatment in the year after their first visit for OCD[6]

LUVOXCR® fluvoxamine maleate extended-release capsules

Label includes boxed warning regarding suicidality and antidepressant drugs. See complete boxed warning at end of presentation.

1. National Institute of Mental Health. http://www.nimh.nih.gov/health/publications/the-numbers-count-mental-disorders-in-america.shtml. Accessed March 3, 2008. 2. Kessler RC, et al. Arch Gen Psychiatry. 2005;62:617-627. 3. Fireman B, et al. Am J Psychiatry. 2001;158:1904-1910. 4. Grabill K et al. Assessment of obsessive-compulsive disorder: a review.J Anxiety Disord. 2008;22(1):1-17. 5. Hales RE, et al (eds). Textbook of Psychiatry. 1999:600-610. 6. Koran LM, et al. Am J Health Syst Pharm. 2000;57:1972-1978.

Luvox CR – Continued Sales Growth

2011 Guidance $32M-$35M[1]



1. Based on guidance provided on July 28, 2011. The company is not updating the prior guidance and actual results may differ.
2. Includes $2.0 million of revenue recorded as a result of a change in the timing of when Luvox CR revenue is recognized. The company now records sales upon shipment to distributors net of estimated returns.

2011 Guidance Reflects High Operating Leverage

	2010A	2011G[1]
Total Product Sales	**$170M**	**$247 – 260M**
Xyrem	$143M	$215 – 225M
Luvox CR	$27M	$32 – 35M
SG&A and R&D Combined	**$95M**	**$105 – 110M**
GAAP Net Income	**$33M**	**$123 – 131M**
Adjusted Net Income[2]	**$61M**	**$145 – 153M**
GAAP EPS	**$0.83**	**$2.68 – $2.79**
Adjusted EPS[2]	**$1.55**	**$3.15 – $3.25**

1. Based on guidance provided on July 28, 2011. The company is not updating the prior guidance and actual results may differ.
2. Adjusted net income and adjusted EPS are non-GAAP financial measures that exclude certain items from GAAP net income and GAAP EPS. A reconciliation of adjusted net income to GAAP net income and the related per share amounts is in a table included with this presentation.

Investment Rationale

- High sales and earnings growth rates
- High margins and high operating leverage
- Significant potential to increase Xyrem sales
- Strong Xyrem exclusivity position including patents extending to 2024
- Potential to leverage existing commercial capabilities with new products
- Disciplined approach to resource allocation

Strategic Transaction with Azur Pharma

AZUR PHARMA

Jazz Pharmaceuticals
Innovation that performs

Compelling Strategic and Financial Benefits



[1] Accretion for Jazz Pharmaceuticals shareholders is on a fully-taxed adjusted EPS basis. Adjusted EPS is a non-GAAP financial measure that exclude certain items from GAAP EPS.
[2] Pro forma estimate as of Jan 1, 2012.

Jazz Pharmaceuticals plc

Portfolio & Financial Projections	• **12 products** currently marketed in US • **>$475 million** in revenues in first 12 months • **>$200 million** in cash generated in first 12 months
Ownership in Combined Company	• Jazz Pharmaceuticals slightly under 80%, Azur Pharma: slightly over 20% • Combined capitalization approximately 60M shares fully diluted at closing
Shareholder Votes	• Jazz Pharmaceuticals board represented funds entered into voting agreements (~43% of shares) • 99% of Azur shareholders entered into agreement to take necessary actions
Board of Directors	• Current directors of Jazz Pharmaceuticals • Seamus Mulligan (Chairman and CEO, Azur Pharma)
Management	• Bruce Cozadd, Chairman and CEO • Kate Falberg, CFO • Seamus Mulligan, Chief Business Officer, International Business Development • Azur executives join JPI executives in leadership roles

Anticipated Closing: 1Q12

Azur Pharma – Compelling Fit With Jazz Pharmaceuticals

- Strong commercial focus and expertise in CNS and women's health
- Key products present new growth opportunities

- Lower risk pipeline of line extensions for clozapine franchise and LCM programs for key women's health brands

A Growing, Diversified Product Portfolio

2011 Estimated Revenues



Benefits of New Corporate Structure

Access to international capital markets and business development opportunities

- Sourcing of new products for all markets
- Potential expansion into Europe

Enhanced management capabilities

- Sales, marketing, and clinical/medical science liaison organizations
- Multi-product supply chain management
- BD executives with demonstrated success

Additional locations (Philadelphia, Dublin)

- Enhanced ability to attract and retain key talent

Parent company in Ireland expected to license, develop and acquire existing and new products

Next Steps

File preliminary proxy statement and S-4

Transaction is subject to customary closing conditions and regulatory approvals, including:

- SEC effectiveness of S-4
- Jazz Pharmaceuticals, Inc. stockholder approval
- Azur approval of other necessary actions
- Antitrust clearance

Expected to close 1Q12

- Transaction will be taxable to Jazz Pharmaceuticals, Inc. stockholders
- Jazz Pharmaceuticals plc shares to be traded on Nasdaq

Compelling Strategic and Financial Benefits



[1] Accretion for Jazz Pharmaceuticals shareholders is on a fully-taxed adjusted EPS basis. Adjusted EPS is a non-GAAP financial measure that excludes certain items from GAAP EPS.
[2] Pro forma estimate as of Jan 1, 2012.

Jazz Pharmaceuticals®

Innovation that performs

Reconciliation of GAAP Net Income and EPS to Adjusted Net Income and EPS in Financial Results and Guidance

	FY 2010	FY 2011G[1]
GAAP net income	$33	$123-131
Add:		
Intangible asset amortization	8	7
Stock-based compensation expense	8	14
Non-cash interest expense	2	2
Loss on extinguishment of debt	12	-
Deduct:		
Contract revenues	(1)	(1)
Luvox CR revenue recognition timing change	(1)	-
Adjusted net income	$61	$145-153
GAAP net income per diluted share (EPS)	$0.83	$2.68-2.79
Adjusted net income per diluted share (EPS)	$1.55	$3.15-3.25
Shares used in computing GAAP and adjusted net income per diluted share amounts	39	46-47

(In millions, except per share amounts)

1. Based on guidance provided on July 28, 2011. The company is not updating the prior guidance and actual results may differ.

Xyrem (sodium oxybate) Boxed Warning

!WARNING: Central nervous system depressant with abuse potential.
Should not be used with alcohol or other CNS depressants.

Sodium oxybate is GHB, a known drug of abuse. Abuse has been associated with some important central nervous system (CNS) adverse events (including death). Even at recommended doses, use has been associated with confusion, depression and other neuropsychiatric events. Reports of respiratory depression occurred in clinical trials. Almost all of the patients who received sodium oxybate during clinical trials were receiving CNS stimulants.

Important CNS adverse events associated with abuse of GHB include seizure, respiratory depression and profound decreases in level of consciousness, with instances of coma and death. For events that occurred outside of clinical trials, in people taking GHB for recreational purposes, the circumstances surrounding the events are often unclear (e.g., dose of GHB taken, the nature and amount of alcohol or any concomitant drugs).

Xyrem is available through the Xyrem Success Program, using a centralized pharmacy (1-866-XYREM88® (1-866-997-3688). The Success Program provides educational materials to the prescriber and the patient explaining the risks and proper use of sodium oxybate, and the required prescription form. Once it is documented that the patient has read and/or understood the materials, the drug will be shipped to the patient. The Xyrem Success Program also recommends patient follow-up every 3 months. Physicians are expected to report all serious adverse events to the manufacturer. (See WARNINGS).

XYREM (sodium oxybate) PI

Luvox CR (fluvoxamine maleate) Boxed Warning

Suicidality and Antidepressant Drugs

Antidepressants increased the risk compared to placebo of suicidal thinking and behavior (suicidality) in children, adolescents, and young adults in short-term studies of major depressive disorder (MDD) and other psychiatric disorders. Anyone considering the use of LUVOX CR® (fluvoxamine maleate) Extended-Release Capsules or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. Short-term studies did not show an increase in the risk of suicidality with antidepressants compared to placebo in adults beyond age 24; there was a reduction in risk with antidepressants compared to placebo in adults aged 65 and older. Depression and certain other psychiatric disorders are themselves associated with increases in the risk of suicide. Patients of all ages who are started on antidepressant therapy should be monitored appropriately and observed closely for clinical worsening, suicidality, or unusual changes in behavior. Families and caregivers should be advised of the need for close observation and communication with the prescriber. LUVOX CR Capsules are not approved for use in pediatric patients. (See WARNINGS: Clinical Worsening and Suicide Risk, PRECAUTIONS: Information for Patients, and PRECAUTIONS: Pediatric Use.)

LUVOX CR (fluvoxamine maleate) PI

Jazz Pharmaceuticals®

Innovation that performs